 Arrowhead Pharmaceuticals Inc NASDAQ: ARWR has voluntarily paused the AROENaC1001 Phase 12 study evaluating ARO-ENaC for cystic fibrosis. ARO-ENaC is the companys investigational RNA interference RNAi therapeutic. 